Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

DARK SECRETS: 17 | Rare Historical Photos

Daily weight loss pill achieves main goal in late-stage trial

Data from an earlier study of the drug in patients without diabetes sent company shares tumbling

The Independent UK

Eli Lilly's Obesity Pill Shows Big Wins In Weight, Blood Sugar And Heart Risk Factors

Eli Lilly and Co. (NYSE:LLY) on Tuesday released topline results from the Phase 3 ATTAIN-2 trial, evaluating oral orforglipron in adults with obesity or overweight and type 2 diabetes.

Benzinga

Diabetes smartphone test could diagnose condition in under 10 minutes

The creators of the world-first app at diagnostics company PocDoc say the test could also save the NHS billions

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

UK firms misleading parents with milk teeth autism treatment claims, report finds

Charity says it is ‘outrageous’ tooth stem cell procedures are being advertised with claims about ‘treating’ autism

The Guardian - UK

Exclusive: Twin Health, metabolic health startup, raises $53 million Series E at $950 million valuation

Twin Health raised a $53 million Series E led by Maj Invest of Denmark, Fortune has exclusively learned.

Fortune

The supplement that could help with weight loss for people with diabetes

Turmeric and curcumin may offer modest benefits for weight management in people with prediabetes and type 2 diabetes, a new study found

The Independent UK

Diabetes patients could be offered weight loss jabs sooner in major shake-up

The changes will impact millions of people with type 2 diabetes in England in the biggest shake-up of care in a decade

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

Type 2 diabetes patients set for major shake-up in care

New draft guidance from the National Institute for Health and Care Excellence suggests the NHS should move away from a one-size-fits-all approach.

The Independent UK

Ozempic Gains First Approval In Canada For Kidney Disease And Cardiovascular Death Risk

Health Canada on Tuesday approved Novo Nordisk's (NYSE:NVO) Ozempic (semaglutide) to reduce the risk of kidney disease and cardiovascular deaths in adults with type 2 diabetes.

Benzinga

Continuous glucose monitors: should people who don’t live with diabetes be wearing them?

Gwyneth Paltrow and other celebrities and influencers are sporting CGMs, but counting your glucose levels provides little benefit if you don’t have diabetes

The Guardian - AU

Half-off Ozempic? US patients paying in cash can now buy the popular weight-loss drug for less

The drug is available as a weight-loss medication under the brand name Wegovy and will now also be sold directly to diabetes patients

The Independent UK

Novo Nordisk slashes price of Ozempic in half to $499 for cash-paying, eligible U.S. patients

The previous out-of-pocket price was nearly $1,000.

Fortune

New study finally busts health myth of much-loved tropical fruit

Clinical trials replaced breakfast bread with a mango and monitored glycemic responses

The Independent UK

Novo Nordisk's Lead Fades, Eli Lilly Holds Course For Outsized Gains, Says Analyst

On Thursday, Eli Lilly and Co. (NYSE:LLY) said it will sharply increase the list price of its weight-loss and type 2 diabetes drug Mounjaro (tirzepatide) in the United Kingdom.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

International Business Times UK

Mounjaro Is About to Get More Expensive in the UK: Here Are Cheaper Alternatives Available Right Now

Mounjaro's UK price will rise by 170% in September, prompting interest in cheaper alternatives like semaglutide for weight loss.

The Guardian - US

Ozempic didn’t work for me. I was furious – and ashamed

Everyone taking the ‘skinny shot’ was losing weight, but my scales didn’t change. My inner dialogue became toxic

The Independent UK

Breakthrough drug that slows onset of type 1 diabetes set for UK release

Teplizumab can allow patients to live “normal lives” without the need for insulin injections

Evening Standard

Drug that slows onset of type 1 diabetes licensed for use in UK-first

The cost-effectiveness of the drug for NHS roll-out will now be assessed by the National Institute for Health and Care Excellence.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Eli Lilly To Raise Mounjaro Price In UK, Expands Obesity Drug Push In India

Eli Lilly and Co. (NYSE:LLY) will sharply increase the list price of its weight-loss and type 2 diabetes drug Mounjaro (tirzepatide) in the United Kingdom, while expanding its market presence in India with a new injector pen.

LiveScience

Diabetic man produces his own insulin after gene-edited cell transplant

The new proof-of-concept study points a way to curing diabetes without the need for immune-suppressing drugs.

Benzinga

Texas Sues Eli Lilly For Alleged Kickback Scheme Involving Mounjaro, Zepbound

Texas Attorney General Ken Paxton has filed a lawsuit against Eli Lilly and Co. (NYSE:LLY), accusing the pharmaceutical giant of bribing medical providers to promote its most profitable drugs, including the widely used GLP-1 medications Mounjaro and Zepbound for diabetes and weight loss.

The Independent UK

The lifestyle medicine that could clear menopausal brain fog

Lifestyle medicine uses interventions to prevent and manage chronic conditions such as heart disease, diabetes and dementia

The Independent UK

Study links weight-loss drugs to serious eye conditions and vision loss

Researchers suggest all diabetes patients on weight-loss drugs should be regularly screened and monitored for potential eye complications

The Conversation

Ozempic and other weight-loss drugs linked to rare but serious eye conditions

Drugs such as Ozempic, Wegovy and Mounjaro (known as semaglutide and tirzepatide) have changed the way clinicians manage diabetes and obesity around the world.

MarketBeat

Trump GLP-1 Pilot Program Could Boost Novo Nordisk & Eli Lilly

Trump’s plan to cover weight loss drugs under Medicaid programs and Medicare Part D plans to could be a major tailwind for LLY and NVO, despite tarrif threats.

1 … 16 17 18 19

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.